Unfinished Upside for BMY

My near-term work argues strongly that Bristol-Myers Squibb (NYSE: BMY) is nearing the completion of its corrective period off of last week’s high at 25.75 into the 24.50 area. Right now I cannot rule out another loop down to revisit 24.50 (last Friday’s low), but if further weakness emerges I will want to enter/add to long positions ahead of unfinished business on the upside that projects to 26.60-27.00 next.

  Matched “”
x
Take Advantage Of Our Free
7-Day Trial, $71st Month Offer!
  • Action-Oriented Trade Set-Ups in Stocks & ETFs
  • Macro Analysis of the Broader Markets
  • Detailed Technical Guidance for each Trading Idea
  • Live Interaction w/ Mike & Our Member Community
  • And Much, Much More!
Join Now! - Special Offer!
Veteran Wall Street analyst and financial author, Mike provides detailed and timely analysis and trade set-ups on a range of markets. Read more...

Have Mike's “Out Front” morning analysis delivered FREE to your email inbox twice weekly!